132 related articles for article (PubMed ID: 16830264)
21. Mucopolysaccharidosis I under enzyme replacement therapy with laronidase--a mortality case with autopsy report.
Lin HY; Lin SP; Chuang CK; Chen MR; Chen BF; Wraith JE
J Inherit Metab Dis; 2005; 28(6):1146-8. PubMed ID: 16435211
[TBL] [Abstract][Full Text] [Related]
22. Transcranial pulsed ultrasound facilitates brain uptake of laronidase in enzyme replacement therapy for Mucopolysaccharidosis type I disease.
Hsu YH; Liu RS; Lin WL; Yuh YS; Lin SP; Wong TT
Orphanet J Rare Dis; 2017 Jun; 12(1):109. PubMed ID: 28595620
[TBL] [Abstract][Full Text] [Related]
23. [The development of cognitive functions in children with Hurler phenotype mucopolysaccharidosis type I on enzyme replacement therapy with laronidase].
Biernacka M; Jakubowska-Winecka A; Tylki-Szymańska A
Pediatr Endocrinol Diabetes Metab; 2010; 16(4):249-54. PubMed ID: 21447265
[TBL] [Abstract][Full Text] [Related]
24. The impact of laronidase treatment in otolaryngological manifestations of patients with mucopolysaccharidosis.
Dualibi AP; Martins AM; Moreira GA; de Azevedo MF; Fujita RR; Pignatari SS
Braz J Otorhinolaryngol; 2016; 82(5):522-8. PubMed ID: 26750310
[TBL] [Abstract][Full Text] [Related]
25. Alpha-L-iduronidase (laronidase; aldurazyme).
Med Lett Drugs Ther; 2003 Oct; 45(1168):88. PubMed ID: 14576624
[No Abstract] [Full Text] [Related]
26. Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase).
Wraith JE; Clarke LA; Beck M; Kolodny EH; Pastores GM; Muenzer J; Rapoport DM; Berger KI; Swiedler SJ; Kakkis ED; Braakman T; Chadbourne E; Walton-Bowen K; Cox GF
J Pediatr; 2004 May; 144(5):581-8. PubMed ID: 15126990
[TBL] [Abstract][Full Text] [Related]
27. Enzyme replacement therapy in two patients with an advanced severe (Hurler) phenotype of mucopolysaccharidosis I.
Tokic V; Barisic I; Huzjak N; Petkovic G; Fumic K; Paschke E
Eur J Pediatr; 2007 Jul; 166(7):727-32. PubMed ID: 17043838
[TBL] [Abstract][Full Text] [Related]
28. [Hurler-Scheie syndrome: monitoring enzyme replacement therapy for two years].
Matilla Fernández B; González Pérez P; de Fuentes Acebes C; Noguerol Cal M; San Martín Sastre JL; Villares García C
Farm Hosp; 2006; 30(5):321-3. PubMed ID: 17166072
[No Abstract] [Full Text] [Related]
29. [Hurler syndrome. Early diagnosis and successful enzyme replacement therapy: a new therapeutic approach. Case report].
Dupont C; El Hachem C; Harchaoui S; Ribault V; Amiour M; Guillot M; Maire I; Froissart R; Guffon-Fouilhoux N
Arch Pediatr; 2008 Jan; 15(1):45-9. PubMed ID: 18162380
[TBL] [Abstract][Full Text] [Related]
30. Scheie syndrome: enzyme replacement therapy does not prevent progression of cervical myelopathy due to spinal cord compression.
Illsinger S; Lücke T; Hartmann H; Mengel E; Müller-Forell W; Donnerstag F; Das AM
J Inherit Metab Dis; 2009 Dec; 32 Suppl 1():S321-5. PubMed ID: 19894140
[TBL] [Abstract][Full Text] [Related]
31. Outcomes of Long-Term Treatment with Laronidase in Patients with Mucopolysaccharidosis Type I.
Laraway S; Mercer J; Jameson E; Ashworth J; Hensman P; Jones SA
J Pediatr; 2016 Nov; 178():219-226.e1. PubMed ID: 27788836
[TBL] [Abstract][Full Text] [Related]
32. Diagnosis and treatment trends in mucopolysaccharidosis I: findings from the MPS I Registry.
D'Aco K; Underhill L; Rangachari L; Arn P; Cox GF; Giugliani R; Okuyama T; Wijburg F; Kaplan P
Eur J Pediatr; 2012 Jun; 171(6):911-9. PubMed ID: 22234477
[TBL] [Abstract][Full Text] [Related]
33. 12 year follow up of enzyme-replacement therapy in two siblings with attenuated mucopolysaccharidosis I: the important role of early treatment.
Gabrielli O; Clarke LA; Ficcadenti A; Santoro L; Zampini L; Volpi N; Coppa GV
BMC Med Genet; 2016 Mar; 17():19. PubMed ID: 26965916
[TBL] [Abstract][Full Text] [Related]
34. Laronidase for cardiopulmonary disease in Hurler syndrome 12 years after bone marrow transplantation.
Valayannopoulos V; de Blic J; Mahlaoui N; Stos B; Jaubert F; Bonnet D; Fischer A; de Lonlay P
Pediatrics; 2010 Nov; 126(5):e1242-7. PubMed ID: 20974778
[TBL] [Abstract][Full Text] [Related]
35. Enzyme replacement therapy in 12 patients with MPS I-H/S with homozygous p.Leu490Pro mutation.
Arora RS; Mercer J; Thornley M; Tylee K; Wraith JE
J Inherit Metab Dis; 2007 Oct; 30(5):821. PubMed ID: 17570076
[TBL] [Abstract][Full Text] [Related]
36. The first 5 years of clinical experience with laronidase enzyme replacement therapy for mucopolysaccharidosis I.
Wraith JE
Expert Opin Pharmacother; 2005 Mar; 6(3):489-506. PubMed ID: 15794739
[TBL] [Abstract][Full Text] [Related]
37. A dose-optimization trial of laronidase (Aldurazyme) in patients with mucopolysaccharidosis I.
Giugliani R; Rojas VM; Martins AM; Valadares ER; Clarke JT; Góes JE; Kakkis ED; Worden MA; Sidman M; Cox GF
Mol Genet Metab; 2009 Jan; 96(1):13-9. PubMed ID: 19038563
[TBL] [Abstract][Full Text] [Related]
38. Early treatment with laronidase improves clinical outcomes in patients with attenuated MPS I: a retrospective case series analysis of nine sibships.
Al-Sannaa NA; Bay L; Barbouth DS; Benhayoun Y; Goizet C; Guelbert N; Jones SA; Kyosen SO; Martins AM; Phornphutkul C; Reig C; Pleat R; Fallet S; Ivanovska Holder I
Orphanet J Rare Dis; 2015 Oct; 10():131. PubMed ID: 26446585
[TBL] [Abstract][Full Text] [Related]
39. [Laronidase for treating post-surgical respiratory failure in a patient with type I mucopolysaccharidosis].
Vélez-Díaz-Pallarés M; Sánchez Cuervo M; Martínez-Pardo Casanova M; Bermejo Vicedo T
Farm Hosp; 2012; 36(1):55-6. PubMed ID: 21641259
[No Abstract] [Full Text] [Related]
40. Intrathecal enzyme replacement therapy: successful treatment of brain disease via the cerebrospinal fluid.
Dickson P; McEntee M; Vogler C; Le S; Levy B; Peinovich M; Hanson S; Passage M; Kakkis E
Mol Genet Metab; 2007 May; 91(1):61-8. PubMed ID: 17321776
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
